Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost

August 3, 2023
Eisai’s group profit leapt 250% year on year in the first quarter of FY2023 as its topline grew on the back of positive mainstay performances and a divestment gain and it saw a decrease in costs associated with an Alzheimer’s...read more